Cervical cancer is the fourth most frequent and fifth most deadly cancer among women worldwide, with the highest incidence in developing countries.

Valéb is being developed to support advancements in cervical precancer treatment. Our goal is to contribute to reducing the burden of cervical cancer and potential complications associated with conventional procedures.